9
Participants
Start Date
June 2, 2021
Primary Completion Date
June 24, 2022
Study Completion Date
July 29, 2022
CNP-201
CNP-201 is comprised of purified peanut extract (PPE) drug substance dispersed within a negatively charged polymer matrix of poly (lactic-co-glycolic acid) (PLGA) particles at a target concentration of \~5 μg of PPE per mg of PLGA.
Placebo
CNP-201 Placebo
Pharmaceutical Research & Consulting, Inc, Dallas
Western Sky Medical Research, El Paso
Medical Research of Arizona, Scottsdale
Peninsula Research Institute, Rolling Hills Estates
Allergy & Asthma Medical Group and Research Center, San Diego
Stanford University School of Medicine / Sean N. Parker Center for Allergy and Asthma Research, Mountain View
Allergy & Asthma Associates of Santa Clara Valley Research Center, San Jose
Seattle Allergy & Asthma, Seattle
Virginia Mason Medical Center, Seattle
Lead Sponsor
COUR Pharmaceutical Development Company, Inc.
INDUSTRY